InertSearch (Application Library)
Index
Application
LC
Micro GC
Document No. Index
LB013 - 100 of Application List
No. | Description | Column |
---|---|---|
LB013 | Analysis of Iohexol and Iopamidol | InertSustain C18 |
LB014 | Analysis of Ergosterol(InertSustain C18) | InertSustain C18 |
LB015 | Analysis of Ergosterol(Inertsil ODS-4) | Inertsil ODS-4 |
LB016 | Analysis of Iminoctadine | InertSustain C18 |
LB017 | Analysis of Furosemide(Under the Condition of Japanese Pharmacopoeia) | Inertsil WP300 C18 |
LB018 | Analysis of Potassium ferricyanide and Potassium ferrocyanide | InertSustain C18 |
LB019 | Analysis of Losartan Potassium and Hydrochlorothiazide | Inertsil C8-4 |
LB020 | Analysis of Losartan Potassium and Hydrochlorothiazide | InertSustain C8 |
LB021 | Analysis of Valsartan and Hydrochlorothiazide | InertSustain C18 |
LB022 | Analysis of Losartan potassium and Valsartan | InertSustain C18 |
LB023 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) | InertSustain C18 |
LB024 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) | InertSustain C18 |
LB025 | Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Hydrate) | InertSustain C18 |
LB026 | Analysis of Pitavastatin Calcium | InertSustain C18 |
LB027 | Analysis of Pitavastatin Calcium | InertSustain C18 |
LB028 | Analysis of Pitavastatin Calcium | InertSustain C18 |
LB029 | Analysis of Pitavastatin Calcium | InertSustain C18 |
LB030 | Analysis of Vitamin K (InertSustain C8) | InertSustain C8 |
LB031 | Analysis of Preservatives and Sweetener | InertSustain Phenyl |
LB032 | Analysis of Malto oligosugars | InertSustain NH2 |
LB033 | Analysis of Vitamin E | InertSustain NH2 |
LB034 | Analysis of Nucleotides | InertSustain NH2 |
LB035 | Analysis of Terbinafine HCl (InertSustain C18) (Under the Condition of Japanese Pharmacopoeia) | InertSustain C18 |
LB036 | Analysis of Terbinafine HCl (Inertsil ODS-3) (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
LB037 | Analysis of Terbinafine HCl (Inertsil ODS-4) (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB038 | Analysis of Chlorantraniliprole (InertSustain C18) | InertSustain C18 |
LB039 | Analysis of Phospholipids (InertSustain C18) | InertSustain C18 |
LB040 | Analysis of Phospholipids (InertSustain C8) | InertSustain C8 |
LB041 | Analysis of Phospholipids (Inertsil ODS-4) | Inertsil ODS-4 |
LB042 | Analysis of 18Drugs(InertSustain C18 2um) | InertSustain C18 |
LB043 | Analysis of 18Drugs(InertSustain C18 HP) | InertSustain C18 |
LB044 | Analysis of Pyridine derivatives (InertSustain C8) | InertSustain C8 |
LB045 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
LB046 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
LB047 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
LB048 | Analysis of Preservatives (Inertsil ODS-4) | Inertsil ODS-4 |
LB049 | Analysis of Pioglitazone(Inertsil ODS-4) | Inertsil ODS-4 |
LB050 | Analysis of Pioglitazone(Inertsil ODS-4) | Inertsil ODS-4 |
LB051 | Analysis of Amlodipine (Inertsil ODS-4) | Inertsil ODS-4 |
LB052 | Analysis of Valsartan (Inertsil ODS-4) | Inertsil ODS-4 |
LB053 | Analysis of Alkylbenzene sulfonate (Inertsil ODS-3) | Inertsil ODS-3 |
LB054 | Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) | InertSustain C8 |
LB055 | Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) | InertSustain C8 |
LB056 | Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) | InertSustain C8 |
LB057 | Analysis of Acetylcysteine (Under the Condition of Japanese Pharmacopoeia 16) | Inertsil ODS-4 |
LB058 | Analysis of Amlodipine Besilate (Under the Condition of Japanese Pharmacopoeia, Amlodipine Besilate Tablets) | InertSustain C18 |
LB059 | Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia) | Inertsil C8-4 |
LB060 | Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine Fumarate Tablets) | Inertsil C8-4 |
LB061 | Analysis of Sarpogrelate Hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) | Inertsil ODS-2 |
LB062 | Analysis of Cetiridine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Cetiridine hydrochloride Tablets) | Inertsil C8-3 |
LB063 | Analysis of Tranilast (InertSustain C18)(Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
LB064 | Analysis of Tranilast (Inertsil ODS-4)(Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB065 | Analysis of Brotizolam(Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C8 |
LB066 | Analysis of Mosapride Citrate Tablets (Under the Condition of Japanese Pharmacopoeia 16) | InertSustain C18 |
LB067 | Analysis of Aripiprazole | InertSustain C18 |
LB068 | Analysis of Olmesartan medoxomil | InertSustain C18 |
LB069 | Analysis of Rosuvastatin Calcium | InertSustain C18 |
LB070 | Analysis of 13 drugs for NSAIDs | InertSustain C18 |
LB071 | Analysis of Esomeprazol (InertSustain C18) | InertSustain C18 |
LB072 | Analysis of Ezetimibe (Inertsil C8-4) | Inertsil C8-4 |
LB073 | Analysis of Irbesartan (Inertsil ODS-4) | Inertsil ODS-4 |
LB074 | Analysis of Rabeprazol (InertSustain C18) | InertSustain C18 |
LB075 | Analysis of Venlafaxine (InertSustain C18) | InertSustain C18 |
LB076 | Analysis of 4 Pesticides (InertSustain C18) | InertSustain C18 |
LB077 | Analysis of 4 Pesticides (InertSustain Phenyl) | InertSustain Phenyl |
LB078 | Analysis of 4 Pesticides (Inertsil ODS-4) | Inertsil ODS-4 |
LB079 | Analysis of 4 Pesticides (Inertsil ODS-3) | Inertsil ODS-3 |
LB081 | Analysis of Fucoxanthin (Inertsil ODS-3) | Inertsil ODS-3 |
LB082 | Analysis of Sertraline hydrochloride (Under the Condition of European Pharmacopoeia 7.0) | Inertsil ODS-3 |
LB083 | Analysis of Ranitidine hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) | ODS |
LB084 | Analysis of Olmesartan medoxomil (Under the Condition of United States Pharmacopeia 35-NF30) | InertSustain C18 |
LB085 | Analysis of Olmesartan medoxomil (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-2 |
LB086 | Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
LB087 | Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia, Naftopidil Tablets) | InertSustain C18 |
LB088 | Analysis of Pre-column Derivatized Amino Acids | Inertsil ODS-4 |
LB089 | Analysis of Phenylenediamine | Inertsil ODS-3 |
LB091 | Analysis of Sinigrin (Inertsil ODS-3) | Inertsil ODS-3 |
LB092 | Analysis of Edaravone (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-3 |
LB093 | Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
LB094 | Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C8 |
LB095 | Analysis of Edaravone Injection (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
LB096 | Analysis of p-Hydroxybenzoic acid methyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB097 | Analysis of p-Hydroxybenzoic acid ethyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB098 | Analysis of p-Hydroxybenzoic acid n-propyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB099 | Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |
LB100 | Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) | Inertsil ODS-4 |